Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

Citations Over TimeTop 10% of 2014 papers

Abstract

Targeted cancer therapies often induce "outlier" responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA sequencing of primary tumor and normal samples from this patient identified a somatic mutation, ARAF S214C, present in the cancer genome and expressed at high levels. Additional mutations affecting this residue of ARAF and a nearby residue in the related kinase RAF1 were demonstrated across 1% of an independent cohort of lung adenocarcinoma cases. The ARAF mutations were shown to transform immortalized human airway epithelial cells in a sorafenib-sensitive manner. These results suggest that mutant ARAF is an oncogenic driver in lung adenocarcinoma and an indicator of sorafenib response.

Related Papers

• → Lung Adenocarcinoma, Mixed Subtype(2010)6 cited
• → Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung(1980)28 cited
• → A rare case of hepatoid adenocarcinoma of the lung(2023)3 cited
• Foetal adenocarcinoma of the lung Foetal adenocarcinoma of the lung Foetal adenocarcinoma of the lung Foetal adenocarcinoma of the lung Foetal adenocarcinoma of the lung(2004)
• → The Profile of Lung Adenocarcinoma Patients with Positive EGFR Mutation(2020)